Alexandria Real Estate Equities (ARE) Stock
Real estate owner of life science campuses for biotech. Here's the price, business snapshot, and what's worth knowing about Alexandria Real Estate Equities in August 2026.
Alexandria Real Estate Equities, Inc. (ARE) is a specialised real‑estate investment trust (REIT) focused on owning, developing and operating life‑science and technology campuses, primarily in the United States. With a market capitalisation of about $13.28 billion, Alexandria leases lab and office space to biotech, pharmaceutical and research companies, often under long‑term agreements that can offer stable rental income but also expose the business to sector cycles. Investors should note the company’s exposure to the health‑science ecosystem, which can drive demand and higher rental premiums but may also concentrate tenant risk. Interest rates, development costs and local real‑estate competition influence cash flow and valuations. Alexandria historically targets income through rents and may offer dividend distributions, yet REIT payouts and share prices can fluctuate. This summary is general educational information and not personalised investment advice; suitability depends on an individual’s circumstances and risk tolerance.
Why It’s Moving
Alexandria Real Estate Shares Slip Amid Q3 Earnings Miss and Softening Life Science Market Outlook
- Q3 2025 results showed a 1.1% drop in occupancy and a 0.9% reduction in projected 2025 same property net operating income, signaling softer demand from life science tenants.
- The company signed a record 16-year build-to-suit lease totaling 466,598 RSF with a multinational pharmaceutical tenant, supporting long-term income streams despite near-term headwinds.
- Significant lease expirations aggregating 1.2 million RSF are expected in early 2026 in major markets like Boston and San Francisco with downtime estimated at 6 to 24 months, increasing vacancy risk and pressuring cash flow.
Alexandria Real Estate Shares Slip Amid Q3 Earnings Miss and Softening Life Science Market Outlook
- Q3 2025 results showed a 1.1% drop in occupancy and a 0.9% reduction in projected 2025 same property net operating income, signaling softer demand from life science tenants.
- The company signed a record 16-year build-to-suit lease totaling 466,598 RSF with a multinational pharmaceutical tenant, supporting long-term income streams despite near-term headwinds.
- Significant lease expirations aggregating 1.2 million RSF are expected in early 2026 in major markets like Boston and San Francisco with downtime estimated at 6 to 24 months, increasing vacancy risk and pressuring cash flow.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping ALEXANDRIA REAL ESTATE EQUITIES stock with a target price of $84.5, indicating potential for growth.
Financial Health
Alexandria Real Estate Equities is showing strong revenue and profits, with healthy cash flow generation.
Dividend
Alexandria Real Estate Equities offers a high dividend yield of 6.15%, making it appealing for income-seeking investors. If you invested $1000 you would be paid $61.50 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Demand for Lab Space
The rise in biotech and research activity can increase demand and rents for specialised lab campuses, though occupancy and returns can fluctuate with the sector cycle.
Specialist Tenant Base
Tenants are often research‑intensive firms, which can support premium pricing but also concentrates risk if the life‑sciences sector slows.
Interest‑Rate Sensitivity
Borrowing costs and property valuations respond to interest‑rate changes, so macro moves can affect cash flow and share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
